July 19, 2012
Oncology is the highest selling indication for pharmaceutical and biotech products. It is projected that global sales of cancer drugs could reach $75-$100 billion by 2016-2020. Currently more than 40% of on-going clinical trials are for cancer indications. There are several factors that play a role in clinical and market success of new emerging cancer drugs. QoL and CEA evidence for market access of cancer drugs?
What are some of the new reimbursement models that are emerging for cancer drugs in the US, EU, LatAm and Asian markets?
How to develop robust budget impact models (PC, iPad, Android formats) and CEA for cancer drugs?
Lessons learned from pricing and reimbursement case studies for CRC, RCC and CML
Webinar 1-1 live in-person replay can be requested by email or phone. Baltimore)
About Novel Health Strategies
Novel Health Strategies, LLC (http://www.novelhealthstrategies.com) is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access strategy. Novel Health team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. Novel Health has large network of internal and external stakeholders and has published several thought leading strategy perspectives, including the 'What's fueling the biotech engine' annual series in Nature Biotech, cited and quoted by more than two hundred peer-reviewed publications and agencies (FDA, EMA and others). BIO meetings.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9710650.htm